Hemab Therapeutics is a clinical-stage biotechnology company developing treatments for serious bleeding and thrombotic disorders. Based in Cambridge, Massachusetts, and Copenhagen, it focuses on coagulation biology and rare conditions such as Glanzmann thrombasthenia, Factor VII deficiency and von Willebrand disease. With little to no product revenue to date, its value centers on advancing prophylactic and disease-modifying therapies for patients with limited existing options.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -15.3 | — |
| Q2 2025 | 0 | — | -12.2 | — |
| Q1 2026 | 0 | — | -22.7 | — |
| Q2 2026 | 0 | — | -24.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Atlanticus Holdings Corporation (ATLC), Bandwidth Inc. (BAND), AnaptysBio, Inc. (ANAB), TriMas Corporation (TRS), Corsair Gaming, Inc. (CRSR), National Vision Holdings, Inc. (EYE)